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Rationale
Cvac is well tolerated with no serious adverse events
related to Cvac treatment in CAN-003. Treatment with
Cvac results in a mucin 1 specific T cell response. In the
second remission patients the median PFS for Cvac was
greater than 12.91 months versus a median PFS for SOC
of 4.94 months (HR 0.32, p = 0.04) and in overall survival
SOC groups had a median of 26.25 months, consistent
with literature but CVac median is not yet reached at
30 months. Thus, based on these compelling PFS signals,
Prima is now moving forward with a 210-patient study of
EOC patients in second remission as compared to stan-
dard of care (SOC).
Trial design
CANVAS is a multinational, multicenter, randomized
trial of Cvac (autologous dendritic cells [DCs] pulsed
with recombinant human fusion protein [mucin 1-glu-
tathione S-transferase] coupled to oxidized polyman-
nose) compared with standard of care as maintenance
treatment in patients with EOC with no evidence of dis-
ease (NED) following second remission defined as after
response to second-line platinum-based therapy.
Eligibility
To be eligible for participation patients must have had
first-line platinum-based chemotherapy with a first remis-
sion lasting for at least 6 months prior to relapse. Patients
must have a second remission defined as: 1) no definitive
evidence of disease detected by computed tomography
(CT) or magnetic resonance imaging (MRI) of the abdo-
men and pelvis; 2) cancer antigen 125 (CA-125) tumor
marker within normal limits OR at least a 90% reduction
from pretreatment levels at the start of second-line plati-
num based therapy; and 3) negative physical exam (i.e., no
clinical signs) following standard platinum-based second-
line chemotherapy (at least 3 cycles). Patients must have a
tumor that over-expresses mucin 1, as well as meet all
other study eligibility criteria.
Objectives
The primary objective is to assess the efficacy, in terms of
overall survival (OS) with the secondary objectives of time
to next treatment (TTNT), progression-free survival (PFS)
and safety and tolerability of Cvac compared with SOC.
Clinical centers
The trial is active in Belgium, Bulgaria, Lithuania, Latvia,
Ukraine and Belarus, with other countries becoming active
such as Germany. Enrolment is underway and metrics will
be presented.
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